Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026)

Protalix BioTherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 84.94% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $7.0 million, a 84.94% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 72.31% from the prior year.
• Operating Leases rose to $7.0 million in Q1 2026 per PLX's latest filing, from $6.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $7.0 million in Q1 2026 and bottomed at $3.8 million in Q1 2025.
• The 5-year median for Operating Leases is $4.2 million (2022), against an average of $4.7 million.
• Across the five-year window, Operating Leases decreased 15.29% in 2025 and jumped 84.94% in 2026, its largest moves.
• Year by year, Operating Leases stood at $4.2 million in 2022, then rose by 10.84% to $4.6 million in 2023, then dropped by 12.88% to $4.0 million in 2024, then surged by 72.31% to $6.9 million in 2025, then grew by 1.6% to $7.0 million in 2026.
• Per Business Quant, the three latest PLX Operating Leases figures stand at $7.0 million (Q1 2026), $6.9 million (Q4 2025), and $6.8 million (Q3 2025).